drug · antibody
sintilimab
Phase 2updated 3mo agoby Innovent Biologics Inc🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for hodgkins lymphoma and 59 investigational indications.
targets
Programmed cell death protein 1
all catalysts(0)
nothing on the calendar yet
Trials studying sintilimab
- phase2A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
- phase3Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
- phase2SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
- phase3A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
- phase1Study of ABO2102 in KRAS-Mutated Solid Tumors
- phase2TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
- phase1Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
- phase3A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
News(1)
- Summit, Merck must navigate new regulatory terrain in China-first cancer landscapeSummit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…biospace · 15d ago
Data sources
last refreshed 41m ago
Found something off?
comments(0)
5-min edit window · permanent after that